Warning letter
Corepharma LLC [ARCHIVED]: warning letter of Jun 21, 2010
FDA warning letter 96446 · New Jersey District Office
Key facts
| Reference number | 96446 |
|---|---|
| Company | Corepharma LLC [ARCHIVED] |
| Subject | Current Good Manufacturing Practice Regulation for Finished Pharmaceuticals |
| Issue date | Jun 21, 2010 |
| Posted date | Jun 21, 2010 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 211.165(f), 211.110(a), 211.110(c), 211.166(a), 211.192, 211.22(d), 211.46(c) |
| Inspection city | Middlesex |
| Inspection ZIP | 08846 |
| Inspection start date | Nov 24, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: